SLC27A5 and hepatocellular carcinoma: This effect is likely due to SLC27A5’s role in promoting cuproptosis in hepatocellular carcinoma via upregulation of FDX1, making it a potential target for cuproptosis induction in this cancer type (Li et al., 2023).